OncoHost, a Binyamina, Israel-based global leader in next-generation precision oncology for improved personalized cancer therapy, announced the completion of a $35 million Series C funding.
The round was led by ALIVE Israel HealthTech VC, a pioneer mid-to-late stage healthtech fund. Additional investors included leading Israeli financial firm Leumi Partners, Israel's largest pension fund Menora Mivtachim, OurCrowd, and other existing investors.
The funding will go towards expanding OncoHost's ongoing multicenter PROPHETIC trial which utilizes PROphet®, the company's machine learning-based host response profiling platform, and supporting the imminent U.S. commercial launch of the precision oncology diagnostic solution.
Round: Series C
Funding Month: May 2022
Lead Investors: ALIVE Israel HealthTech VC
Additional Investors: Leumi Partners, Menora Mivtachim, and OurCrowd
Company Website: https://oncohost.com/
Software Category: AI-Powered Precision Oncology Platform
About the Company: OncoHost combines life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of cancer therapy. Utilizing proprietary proteomic analysis, the company aims to understand patients' unique responses to therapy and overcome one of the major obstacles in clinical oncology today – resistance to therapy. OncoHost's host response profiling platform, PROphet®, analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient (i.e., the host) in response to given cancer therapy. Leveraging advanced proteomic analysis and AI-based host response science, OncoHost's PROphet® platform is a personalized, real-time, dynamic 'disease navigator' that provides early identification of an individual's responsiveness to cancer therapy, analysis of treatment resistance mechanisms, and potentially available strategies to overcome this resistance. PROphet® also identifies potential drug targets, advancing the development of novel therapeutic strategies as well as rationally based combination therapies.